The company now projects revenues between $725-750 million for the year, up from its original guidance of over $600 million, though InvestingPro analysis indicates the company faces profitability ...

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

According to InvestingPro analysis, five analysts have revised their earnings ... Relay faces challenges from established players like AstraZeneca (NASDAQ:AZN)’s Capivasertib and emerging competitors ...

According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 3.86%, which means ...

Morgan Stanley’s analysis from November 2024 projected significant revenue growth, with estimates rising from RMB 123,851 million in 2023 to RMB 202,461 million by 2026. However, earnings per share ...

According to InvestingPro analysis, the stock is currently trading slightly below its Fair Value, suggesting potential upside opportunity. This comprehensive analysis delves into the company’s current ...

AstraZeneca reaffirmed that data on the key secondary endpoints of overall survival or time to second disease progression (PFS2) had been immature at the time of the interim analysis. All the ...

Eli Lilly LLY and AstraZeneca AZN are leading drugmakers with significant involvement in oncology, immunology, and the cardiometabolic disease space. Both are making substantial investments in ...

And for seven years, it has been almost assumed that the medicines generating the most buzz will come from AstraZeneca. Perhaps that’s why, in a wood-paneled conference room at the St. Regis ...